Journal of gynecology obstetrics and human reproduction · 2019
The results of new low dose fractional CO2 Laser - A prospective clinical study in France.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Marin Jan, Lipa Greta, Dunet Eric
Аннотация
OBJECTIVES: The aim of this research was to assess the efficacy of the new generation micro-fractional CO2 laser low dose energy (Aphrodite, BH LASER, France) in the treatment of genitourinary syndrome.
MATERIALS AND METHODS: This prospective interventional clinical study, included a total of 25 menopausal symptomatic patients and 25 non-menopausal symptomatic patients having symptoms of vulvovaginal atrophy. There were only two laser sessions spaced at 6 weeks. It was evaluated the Female Sexual Function Index (FSFI) and the QoL at baseline, 3 and 6 months.
RESULTS: The study showed a significant improvement in both groups when assessing FSFI scores at 3- and 6-months follow-up compared to baseline (p<0.05) and secondary it was observed a significant initial improvement of QoL score at 3 and 6 months (p<0.05), compared to baseline. There were no important adverse events registered during the study period.
CONCLUSIONS: The new micro-fractionated laser device with low dose energy - 18W, demonstrated significant improvement of genitourinary syndrome in both non-menopausal and post-menopausal women with no important adverse event.
MATERIALS AND METHODS: This prospective interventional clinical study, included a total of 25 menopausal symptomatic patients and 25 non-menopausal symptomatic patients having symptoms of vulvovaginal atrophy. There were only two laser sessions spaced at 6 weeks. It was evaluated the Female Sexual Function Index (FSFI) and the QoL at baseline, 3 and 6 months.
RESULTS: The study showed a significant improvement in both groups when assessing FSFI scores at 3- and 6-months follow-up compared to baseline (p<0.05) and secondary it was observed a significant initial improvement of QoL score at 3 and 6 months (p<0.05), compared to baseline. There were no important adverse events registered during the study period.
CONCLUSIONS: The new micro-fractionated laser device with low dose energy - 18W, demonstrated significant improvement of genitourinary syndrome in both non-menopausal and post-menopausal women with no important adverse event.